Ischemic stroke is caused by occlusion of cerebral arteries that are inaccessible by intra-arterial catheters. Therefore, reperfusion with thrombolytics will remain an important treatment for hyperacute ischemic stroke. Ace Therapeutics is a stroke-focused preclinical CRO company, offering clients one-stop thrombolytics development services.
Thrombolytic agents were first discovered from bacteria (streptokinase, staphylococcal kinase), tissues (fibrin kinase), urine (urokinase), or substances from bat saliva that can activate the fibrinolytic system. Recombinant tissue plasminogen activator (rt-PA) is the only established acute thrombolytic treatment option for ischemic stroke. However, rt-PA still often fails to achieve rapid reperfusion, has relatively low recanalization rates, and is associated with an increased risk of bleeding. There is an unmet need for novel thrombolytic agents with better benefit-risk than rt-PA. Pharmaceutical companies need to step up their efforts to develop new compounds faster to bring hope to more stroke patients.
Fig. 1. Molecular structure and fibrinolytic function of tissue plasminogen activator (tPA). (Nikitin et al., 2021)
Ace Therapeutics has a team of experts in biochemistry, pharmacology and drug development with a comprehensive understanding of the preclinical research pipeline in stroke and the current state of thrombolytics. Our strong capabilities and technologies in the field of stroke contribute to the development of novel thrombolytics. We offer comprehensive services covering every stage of the stroke drug development process, from target identification to preclinical evaluation.
Ace Therapeutics offers a variety of molecular biology methods and computational approaches to find molecules with thrombolytic activity in different organisms.
We can use a combination of methods to help our clients screen a wider range of molecules and increase the likelihood of finding good targets, while testing the biophysical, biochemical and biological properties of thrombolytic candidates.
We provide rational protein design services to determine the crystal structure of thrombolytic enzymes and use them for computer modeling. We aim to improve the half-life, potency, solubility, and fibrin affinity of thrombolytics.
We offer a variety of in vitro assays to evaluate individual properties affected by structural modifications of thrombolytics.
Our available thromboembolic models (e.g., clot injection-induced thromboembolic stroke model, in situ thrombosis model, FeCl3-induced thromboembolic model, photochemical thrombosis model) can be used to test the efficacy and safety of thrombolytics. We offer a range of stroke-related endpoint measurements.
Ace Therapeutics offers customized thrombolytics development services to help clients develop safe and effective thrombolytics for stroke. Whether it is target identification or preclinical experimental design, we work closely with our partners to develop a comprehensive strategy that meets their goals and timelines. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.